Mon, February 11, 07:40am
Robert W. Baird reissued their outperform rating on shares of Newlink Genetics Cor (NASDAQ: NLNK) in a report released on Monday. Robert W. Baird currently has a $20.00 target price on the stock.
Separately, analysts at MLV Capital initiated coverage on shares of Newlink Genetics Cor in a research note to investors on Thursday, January 3rd. They set a buy rating and a $18.50 price target on the stock.
Shares of Newlink Genetics Cor traded up 2.45% during mid-day trading on Monday, hitting $12.53. Newlink Genetics Cor has a 52 week low of $7.23 and a 52 week high of $18.00. The stock's 50-day moving average is currently $11.84. The company's market cap is $262.1 million.
NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
Read more: http://www.jagsreport.com/2013/02/robert-w-baird-reaffirms-outperform-rating-on-newlink-genetics-cor-nlnk/